Synthesis and anti-HCV activity of 4-hydroxyamino α-pyranone carboxamide analogues

ACS Medicinal Chemistry Letters

Volumn 5, Issue 3, 2014, Pages 259-263

  Konreddy, Ananda Kumar ^a   Toyama, Massaki ^b   Ito, Wataru ^b   Bal, Chandralata ^a   Baba, Masanori ^b   Sharon, Ashoke ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; non nucleoside inhibitor; pyranone carboxamide

Indexed keywords

4 HYDROXYAMINO ALPHA PYRANONE CARBOXAMIDE; AMIDE; ANTIVIRUS AGENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NESBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; X RAY DIFFRACTION;

EID: 84896370090     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400432f     Document Type: Article

References (25)

1. Lavanchy, D. Evolving epidemiology of hepatitis C virus Clin. Microbiol. Infect. 2011, 17, 107-115
2. Thomas, D. L. Global control of hepatitis C: where challenge meets opportunity Nat. Med. 2013, 19, 850-858
3. Liang, T. J. Current progress in development of hepatitis C virus vaccines Nat. Med. 2013, 19, 869-878
4. Houghton, M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses Immunol. Rev. 2011, 239, 99-108
5. Manns, M. P.; von Hahn, T. Novel therapies for hepatitis C: one pill fits all? Nat. Rev. Drug Discovery 2013, 12, 595-610
6. Bartenschlager, R.; Lohmann, V.; Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat. Rev. Microbiol. 2013, 11, 482-496
7. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
8. Poordad, F.; McCone, J., Jr.; Bacon, B. R.; Bruno, S.; Manns, M. P.; Sulkowski, M. S.; Jacobson, I. M.; Reddy, K. R.; Goodman, Z. D.; Boparai, N.; DiNubile, M. J.; Sniukiene, V.; Brass, C. A.; Albrecht, J. K.; Bronowicki, J. P.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 2011, 364, 1195-1206
9. Jacobson, I. M.; McHutchison, J. G.; Dusheiko, G.; Di Bisceglie, A. M.; Reddy, K. R.; Bzowej, N. H.; Marcellin, P.; Muir, A. J.; Ferenci, P.; Flisiak, R.; George, J.; Rizzetto, M.; Shouval, D.; Sola, R.; Terg, R. A.; Yoshida, E. M.; Adda, N.; Bengtsson, L.; Sankoh, A. J.; Kieffer, T. L.; George, S.; Kauffman, R. S.; Zeuzem, S.; Team, A. S. Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 2011, 364, 2405-2416
10. Jiang, Y.; Andrews, S. W.; Condroski, K. R.; Buckman, B.; Serebryany, V.; Wenglowsky, S.; Kennedy, A. L.; Madduru, M. R.; Wang, B.; Lyon, M.; Doherty, G. A.; Woodard, B. T.; Lemieux, C.; Do, M. G.; Zhang, H.; Ballard, J.; Vigers, G.; Brandhuber, B. J.; Stengel, P.; Josey, J. A.; Beigelman, L.; Blatt, L.; Seiwert, S. D. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease J. Med. Chem. 2013, 10.1021/jm400164c
11. Moreau, B.; O'Meara, J. A.; Bordeleau, J.; Garneau, M.; Godbout, C.; Gorys, V.; Leblanc, M.; Villemure, E.; White, P. W.; Llinas-Brunet, M. Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution J. Med. Chem. 2013, 10.1021/jm400121t
12. Manns, M. P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications Gut 2006, 55, 1350-1359
13. Sarrazin, C.; Hezode, C.; Zeuzem, S.; Pawlotsky, J. M. Antiviral strategies in hepatitis C virus infection J. Hepatol. 2012, 56 (Suppl 1) S88-S100
14. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase J. Med. Chem. 2012, 55, 2481-2531
15. Kasula, M.; Balaraju, T.; Toyama, M.; Thiyagarajan, A.; Bal, C.; Baba, M.; Sharon, A. A conformational mimetic approach for the synthesis of carbocyclic nucleosides as Anti-HCV leads ChemMedChem 2013, 8, 1673-1680
16. Schoenfeld, R. C.; Bourdet, D. L.; Brameld, K. A.; Chin, E.; de Vicente, J.; Fung, A.; Harris, S. F.; Lee, E. K.; Le Pogam, S.; Leveque, V.; Li, J.; Lui, A. S.; Najera, I.; Rajyaguru, S.; Sangi, M.; Steiner, S.; Talamas, F. X.; Taygerly, J. P.; Zhao, J. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B J. Med. Chem. 2013, 10.1021/jm401266k
17. Poordad, F.; Lawitz, E.; Kowdley, K. V.; Cohen, D. E.; Podsadecki, T.; Siggelkow, S.; Heckaman, M.; Larsen, L.; Menon, R.; Koev, G.; Tripathi, R.; Pilot-Matias, T.; Bernstein, B. Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 2013, 368, 45-53
18. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.; Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.; Lewis, C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor J. Med. Chem. 2009, 52, 1255-1258
19. Tedesco, R.; Shaw, A. N.; Bambal, R.; Chai, D.; Concha, N. O.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; Gerhardt, W. G.; Halegoua, D. L.; Han, C.; Hofmann, G. A.; Johnston, V. K.; Kaura, A. C.; Liu, N.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Wiggall, K. J.; Zimmerman, M. N.; Duffy, K. J. 3-(1,1-Dioxo-2 H -(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1 H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase J. Med. Chem. 2006, 49, 971-983
20. Cheng, C. C.; Huang, X.; Shipps, G. W.; Wang, Y.-S.; Wyss, D. F.; Soucy, K. A.; Jiang, C.-K.; Agrawal, S.; Ferrari, E.; He, Z.; Huang, H. C. Pyridine carboxamides: Potent palm site inhibitors of HCV NS5B Polymerase ACS Med. Chem. Lett. 2010, 1, 466-471
21. Karampuri, S.; Bag, P.; Yasmin, S.; Chouhan, D. K.; Bal, C.; Mitra, D.; Chattopadhyay, D.; Sharon, A. Structure based molecular design, synthesis and biological evaluation of alpha-pyrone analogs as anti-HSV agent Bioorg. Med. Chem. Lett. 2012, 22, 6261-6266
22. Tominaga, Y.; Ushirogochi, A.; Matsuda, Y. Synthesis and reaction of 6-substituted 3-methoxycarbonyl-4-methylthio-2 H -pyran-2-one derivatives J. Heterocycl. Chem. 1987, 24, 1557-1567
23. Salim, M. T.; Aoyama, H.; Sugita, K.; Watashi, K.; Wakita, T.; Hamasaki, T.; Okamoto, M.; Urata, Y.; Hashimoto, Y.; Baba, M. Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives Biochem. Biophys. Res. Commun. 2011, 415, 714-719
24. Goto, K.; Watashi, K.; Murata, T.; Hishiki, T.; Hijikata, M.; Shimotohno, K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811 Biochem. Biophys. Res. Commun. 2006, 343, 879-884
25. Ishii, N.; Watashi, K.; Hishiki, T.; Goto, K.; Inoue, D.; Hijikata, M.; Wakita, T.; Kato, N.; Shimotohno, K. Diverse effects of cyclosporine on hepatitis C virus strain replication J. Virol. 2006, 80, 4510-4520 Science and Technology Science and Technology